Skip to main content

Table 1 LDCT in lung cancer screening

From: Lung cancer screening: from imaging to biomarker

Trial Name Study design No. recruited Characteristics of participants Exsmoker quit (yrs) Year started Report date LC baseline rate (LDCT) Stage I Cancer at Baseline
Age Sex Smoker(PkYr)
NLST [47] LDCT vs CXR 53454 55–74 M/F >=30 <15 2002 2011 1.0% 63.0%
NELSON [42, 95] LDCT vs UC 15822 50–75 M/F 15–18.75 <10 2003 2016 0.9% 63.9%
ITALUNG [39] LDCT vs UC 3206 55–69 M/F >=20 <10 2004 NR 1.5% 47.6%
DEPISCAN [38] LDCT vs CXR 765 50–75 M/F >=15 <15 2002 2006 2.38% 0.9%
DANTE [37, 96] LDCT vs UC 2472 60–74 M >=20 <10 2001 2007 2.2% 57%
DLCST [97] LDCT vs UC 4104 50–70 M/F >=20 <10 2004 2016 0.8% 58.8%
LSS [34, 36] LDCT vs CXR 3318 55–77 M/F >=30 <10 2000 2005 1.9% 53.3%
  1. LDCT= low-dose computed tomography; CXR=chest X-ray; NC=usual care; M=male; F=female; PkYr=packs/year; yrs=years; f/u=follow-up; NR=not reported; LC=lung cancer.